Induced pluripotent stem cells (iPSCs) are terminally differentiated somatic cells that
differentiate into various cell types. iPSCs are expected to be used for disease modeling and …

The breakthrough development of induced pluripotent stem cell (iPSC) technology is not
only revolutionizing basic stem cell science but is also spurring efforts to reprogram one …

Discovery of induced pluripotent stem (iPS) cells in 2006 provided a new path for cell
transplantation and drug screening. The iPS cells are stem cells derived from somatic cells …

Highlights•Preclinical animal models are not reliable for human clinical trials.•Post-
marketing failure and black box warnings of approved market drugs are shown.•Key gates …

Disease‐specific pluripotent stem cells are a source of affected cell types for drug discovery.
The ability to reprogram somatic cells into induced pluripotent stem cells (iPSCs) provides a …

The induced pluripotent stem cell (i PSC) technology is instrumental in advancing the fields
of disease modeling and cell transplantation. We herein discuss the various issues …

Abstract In 2006, Shinya Yamanaka first reported that in vitro reprogramming of somatic cells
toward pluripotency was achieved by simple induction of specific transcription factors …

The advent of induced pluripotent stem cell (iPSC) technology, which allows to transform
one cell type into another, holds the promise to produce therapeutic cells and organs on …

With the general decline of pharmaceutical research productivity, there are concerns that
many components of the drug discovery process need to be redesigned and optimized. For …

Human pluripotent stem cells bring promise in regenerative medicine due to their self‐
renewing ability and the potential to become any cell type in the body. Moreover, pluripotent …